About this Medicine article

Tumour Biomarkers: Association with Heart Failure Outcomes by C. Shi; H. H. van der Wal; H. H. W. Silljé; M. M. Dokter; F. van den Berg; L. Huizinga; M. Vriesema; J. Post; S. D. Anker; J. G. Cleland; L. L. Ng; N. J. Samani; K. Dickstein; F. Zannad; C. C. Lang; P. L. van Haelst; J. A. Gietema; M. Metra; P. Ameri; M. Canepa; D. J. van Veldhuisen; A. A. Voors; R. A. de Boer is a Medicine article available to read on EtoBox.

## Abstract ## Background There is increasing recognition that heart failure (HF) and cancer are conditions with a number of shared characteristics. ## Objectives To explore the association between tumour biomarkers and HF outcomes. ## Methods In 2,079 patients of BIOSTAT‐CHF cohort, we measured six established tumour biomarkers: CA125, CA15‐3, CA19‐9, CEA, CYFRA 21‐1 and AFP. ## Results During a median follow‐up of 21 months, 555 (27%) patients reached the primary end‐point of all‐cause mortality. CA125, CYFRA 21‐1, CEA and CA19‐9 levels were positively correlated with NT‐proBNP quartiles (all P < 0.001, P for trend < 0.001) and were, respectively, associated with a hazard ratio of 1.17 (95% CI 1.12–1.23; P < 0.0001), 1.45 (95% CI 1.30–1.61; P < 0.0001), 1.19 (95% CI 1.09–1.30; P = 0.006) and 1.10 (95% CI 1.05–1.16; P < 0.001) for all‐cause mortality after correction for BIOSTAT risk model (age, BUN, NT‐proBNP, haemoglobin and beta blocker). All tumour biomarkers (except AFP) had significant associations with secondary end‐points (composite of all‐cause mortality and HF hospitalization, HF hospitalization, cardiovascular (CV) mortality and non‐CV mortality). ROC curves showed the

Author

C. Shi; H. H. van der Wal; H. H. W. Silljé; M. M. Dokter; F. van den Berg; L. Huizinga; M. Vriesema; J. Post; S. D. Anker; J. G. Cleland; L. L. Ng; N. J. Samani; K. Dickstein; F. Zannad; C. C. Lang; P. L. van Haelst; J. A. Gietema; M. Metra; P. Ameri; M. Canepa; D. J. van Veldhuisen; A. A. Voors; R. A. de Boer

Publisher

John Wiley and Sons; Wiley (Blackwell Publishing); Blackwell Publishing Inc.; Wiley (ISSN 0954-6820)

Published

2020

Language

EN

Field

Medicine (Health Sciences)